Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: cinieri s. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L. Vitolo U, et al. Among authors: cinieri s. J Clin Oncol. 1997 Feb;15(2):491-8. doi: 10.1200/JCO.1997.15.2.491. J Clin Oncol. 1997. PMID: 9053470
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. De Pas T, et al. Among authors: cinieri s. Ann Oncol. 2000 Jul;11(7):821-7. doi: 10.1023/a:1008319923516. Ann Oncol. 2000. PMID: 10997809 Free article. Clinical Trial.
NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey.
Pagano L, Gallamini A, Trapè G, Fianchi L, Mattei D, Todeschini G, Spadea A, Cinieri S, Iannitto E, Martelli M, Nosari A, Bona ED, Tosti ME, Petti MC, Falcucci P, Montanaro M, Pulsoni A, Larocca LM, Leone G; Intergruppo Italiano Linfomi. Pagano L, et al. Among authors: cinieri s. Ann Oncol. 2006 May;17(5):794-800. doi: 10.1093/annonc/mdl015. Epub 2006 Feb 23. Ann Oncol. 2006. PMID: 16497823 Free article.
Management of advanced breast cancer.
Orlando L, Colleoni M, Fedele P, Cusmai A, Rizzo P, D'Amico M, Chetri MC, Cinieri S. Orlando L, et al. Among authors: cinieri s. Ann Oncol. 2007 Jun;18 Suppl 6:vi74-6. doi: 10.1093/annonc/mdm230. Ann Oncol. 2007. PMID: 17591838 Free article. Review.
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G; International Breast Cancer Study Group. Ravaioli A, et al. Ann Oncol. 2008 Apr;19(4):660-8. doi: 10.1093/annonc/mdm547. Epub 2008 Feb 13. Ann Oncol. 2008. PMID: 18272916 Free article. Clinical Trial.
Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA Jr, Pruneri G, Cocorocchio E, Cinieri S, Raviele PR, Bassi S, Preda L, Martinelli G, Peccatori FA. Azim HA Jr, et al. Among authors: cinieri s. Oncology. 2009;76(1):26-9. doi: 10.1159/000177953. Epub 2008 Nov 24. Oncology. 2009. PMID: 19033694
Adjuvant endocrine treatment in premenopausal early breast cancer.
Orlando L, Fedele P, Cinefra M, Sponziello F, Calvani N, Chetrì MC, Rizzo P, D'Amico M, Schiavone P, Portaluri M, Criscuolo M, Burlizzi S, Cinieri S. Orlando L, et al. Among authors: cinieri s. Oncology. 2009;77 Suppl 1:9-13. doi: 10.1159/000258490. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130426 Review.
Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
Galetta D, Pisconti S, Cinieri S, Pappagallo GL, Gebbia V, Borsellino N, Maiello E, Rinaldi A, Montrone M, Rizzo P, Marzano N, Sasso N, Febbraro A, Colucci G. Galetta D, et al. Among authors: cinieri s. Clin Lung Cancer. 2011 Nov;12(6):402-6. doi: 10.1016/j.cllc.2011.06.006. Epub 2011 Aug 10. Clin Lung Cancer. 2011. PMID: 21831718 Clinical Trial.
276 results